NCT00263523

Brief Summary

This study will use positron emission tomography (PET) and magnetic resonance imaging (MRI) to measure a serotonin receptor subtype in the brain called 5-HT(1A). This receptor is a target for drug therapy to treat anxiety and depression. The study will see if a newly developed radioligand (radioactive substance used in PET scanning to study the receptor systems of the brain) called \[(11)C\](-)-RWAY is more effective than other radioligands currently used in brain receptor research. Healthy subjects 18-40 years of age may be eligible for this study. Candidates are screened with a physical examination, electrocardiogram, and blood and urine tests. Participants undergo PET and MRI scanning as follows: PET scan PET uses small amounts of a radioactive chemical called a tracer (in this case, \[(11)C\](-)-RWAY) that "labels" active areas of the brain. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the subject's head and attached to the bed to help keep the head still during the scan so the images will be clear. A brief scan is done just before the tracer is injected to provide measures of the brain that will help in the precise calculation of information from subsequent scans. Then, the tracer is injected through a catheter (plastic tube) placed in the arm and pictures are taken for about 2 hours, while the subject lies still on the scanner bed. Subjects return to the clinic for blood and urine tests 24 hours after the scan. MRI The MRI scan is done within 1 year of the PET scan. MRI uses a magnetic field and radio waves to produce images of body tissues and organs-in this case, the brain. The subject lies on a table that is moved into the scanner (a tube-like device), wearing earplugs to muffle the noise of the machine during the scanning process. The space in the scanner is confining and may cause some people to be somewhat anxious. An intercom system allows the subject to speak with the staff member performing the study at all times during the procedure, and the procedure can be stopped at any time.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for phase_1 healthy-volunteers

Timeline
Completed

Started Dec 2005

Longer than P75 for phase_1 healthy-volunteers

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 5, 2005

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

December 8, 2005

Completed
Same day until next milestone

First Posted

Study publicly available on registry

December 8, 2005

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 15, 2007

Completed
Last Updated

July 2, 2017

Status Verified

August 15, 2007

First QC Date

December 8, 2005

Last Update Submit

June 30, 2017

Conditions

Keywords

SerotoninPositron Emission TomograhyBrainNeurochemistryNeurotransmitterHealthy VolunteerHV

Interventions

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All subjects must be healthy and aged 18-65 years.

You may not qualify if:

  • Current psychiatric illness, substance abuse or severe systemic disease based on history and physical exam.
  • Any existing physical exam and ECG within one year will be reviewed and if none already exists in the chart, these will be obtained and reviewed.
  • Laboratory tests with clinically significant abnormalities.
  • Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
  • Pregnancy and breast feeding.
  • Claustrophobia.
  • Presence of ferromagnetic metal in the body or heart pacemaker.
  • Positive HIV test.
  • A history of brain disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (1)

  • Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997 Nov;38(11):1818-23.

    PMID: 9374364BACKGROUND

MeSH Terms

Interventions

2, 3, 4, 5, 6, 7-hexahydro-1(4-(1(4-(2-methoxyphenyl)-piperazinyl))-2-phenylbutyry)-1H-azepine

Study Design

Study Type
interventional
Phase
phase 1
Purpose
TREATMENT
Sponsor Type
NIH

Study Record Dates

First Submitted

December 8, 2005

First Posted

December 8, 2005

Study Start

December 5, 2005

Study Completion

August 15, 2007

Last Updated

July 2, 2017

Record last verified: 2007-08-15

Locations